Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$43.2B
4,404M shares
52-week range
$8.65 – $11.28
41% from low
Exchange
NYSE
ADRC
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
www.haleon.comNo one on the platform currently holds HLN.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 1,434,399 | $12.9M |
| Bridgewater Associatesas of 2024-06-30 | 189,557 | $1.6M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-08-14 | $0.0642 | 2026-09-17 |
| 2026-04-10 | $0.1333 | 2026-05-14 |
| 2025-08-15 | $0.0598 | 2025-09-18 |
| 2025-04-25 | $0.1246 | 2025-06-05 |
| 2024-08-16 | $0.0527 | 2024-09-19 |
| 2024-03-14 | $0.1053 | 2024-05-16 |
| 2023-08-24 | $0.0439 | 2023-10-05 |
No one on the platform has traded HLN yet.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $11.4B | +3.3% | $0.42 | $0.41–$0.42 | 23.3× | 3 |
| 2027 | $11.9B | +4.2% | $0.46 | $0.45–$0.47 | 21.3× | 5 |
| 2028 | $12.4B | +4.3% | $0.50 | $0.48–$0.53 | 19.5× | 6 |
| 2029 | $12.9B | +3.8% | $0.54 | $0.53–$0.55 | 18.0× | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $0.27 | $0.28 | +3.6% |
| 2026-02-25 | $0.25 | $0.26 | +3.4% |
| 2025-07-31 | $0.24 | $0.24 | -0.6% |
| 2025-02-27 | $0.22 | $0.23 | +5.2% |
| 2024-10-31 | $0.11 | $0.23 | +109.4% |
| 2024-05-01 | $0.11 | $0.12 | +9.1% |
| 2023-08-02 | $0.22 | $0.22 | -1.6% |
| 2023-03-02 | $0.13 |
| $0.21 |
| +61.8% |
| $54.2B |
| — |
| HUMHumana Inc. | $384.97 | -0.99% | $46.2B | — |
| INSMInsmed Incorporated | $126.33 | -4.50% | $27.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.